MedTrace Logo

A Study to Determine the Safety and Efficacy of Atralin (Tretinoin 0.05%) Gel for the Treatment of Rosacea

NCT00621218 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2008-12-18

No results posted yet for this study

Summary

To compare the efficacy and safety of tretinoin gel 0.05% to its vehicle when dosed once or twice daily in female subjects with rosacea.

Conditions

  • Rosacea

Interventions

DRUG

tretinoin gel 0.05%

Apply tretinoin gel, 0.05% topically once or twice daily to female subjects with rosacea

DRUG

vehicle

Apply Atralin Gel vehicle topically once or twice daily to female subjects with rosacea.

Sponsors & Collaborators

  • Coria Laboratories, Ltd.

    lead INDUSTRY

Principal Investigators

  • Morris V Shelanski, MD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2008-04-30
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00621218 on ClinicalTrials.gov